Details

Autor(en) / Beteiligte

• Chiang, Kuang‐Chung
• Lai, Chung‐Yu
• Chiou, Hui‐Ling
• Lin, Chia‐Liang
• Chen, Yong‐Syuan
• Kao, Shao‐Hsuan
• Hsieh, Yi‐Hsien

Titel

Timosaponin AIII inhibits metastasis of renal carcinoma cells through suppressing cathepsin C expression by AKT/miR‐129‐5p axis

Ist Teil von

• Journal of cellular physiology, 2019-08, Vol.234 (8), p.13332-13341

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2019

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Timosaponin AIII (TSAIII) is a steroidal saponin that exerts anticancer activity on various cancer cells. In this study, we explore the effects of TSAIII on renal cell carcinoma (RCC) cells. Our findings show that TSAIII treatment (<8 μM) insignificantly influenced cell viability and cell cycle distribution of human RCC cell lines 786‐O, A‐498, and ACHN. Further observations revealed that TSAIII inhibited migration and invasion of 786‐O and A‐498 cells, as well as significantly decreased the production and expression of cathepsin C (CTSC) in both the cell types. Kinase cascade analysis exhibited that PI3K/AKT activation was inhibited, but PTEN expression was increased, in response to TSAIII treatments. Combining TSAIII and PI3K inhibitors, LY294002 synergically reduced the migration and invasion of 786‐O and A‐498 cells, as well as decreased the CTSC expression in both the cell types. We also observed that miR‐129‐5p bound to CTSC gene and suppressed the expression of CTSC and demonstrated that the miR‐129‐5p expression was synergically enhanced by TSAIII and LY294002. In addition, pretreatment with antago‐miR‐129‐5p significantly restored the CTSC expression and the migration and invasion of TSAIII‐treated 786‐O cells. In conclusion, our findings reveal that TSAIII inhibits the metastatic properties of RCC cells, contributing to the inhibition of PI3K/AKT and the increase of miR‐129‐5p and the subsequent downregulation of CTSC. This suggests that TSAIII has significant antimetastatic activity against RCC cells and may be beneficial to RCC treatments. Antimetastatic activity of TSAIII against RCC cells by induction of miR‐129‐5p targets CTSC expression.